4//SEC Filing
Moxie Dwight 4
Accession 0001479290-23-000098
CIK 0001479290other
Filed
Aug 14, 8:00 PM ET
Accepted
Aug 15, 4:15 PM ET
Size
6.9 KB
Accession
0001479290-23-000098
Insider Transaction Report
Form 4
Moxie Dwight
CLO & GC
Transactions
- Award
Common Stock
2023-08-11+19,346→ 88,511 total - Tax Payment
Common Stock
2023-08-11$18.91/sh−9,592$181,385→ 78,919 total
Footnotes (2)
- [F1]Represents the vesting of a performance-based restricted stock award (PSA) granted on February 2, 2021. On August 11, 2023, the Issuer's Compensation Committee certified 100% of the PSAs eligible to vest based on (i) the achievement of a cumulative revenue goal, calculated in accordance with GAAP, adjusted to exclude revenue recognized from collaboration agreements and classified as collaboration revenue, measured beginning on January 1, 2021, provided the goal is achieved on or before the three-year anniversary of the U.S. Food and Drug Administration's approval of the Issuer's biologics license application for DAXXIFY(R) for the improvement of glabellar lines, and (ii) subject to the Reporting Person remaining in continuous service through the vesting date.
- [F2]Represents the number of shares withheld by and surrendered to the Issuer on August 11, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the PSA.
Documents
Issuer
Revance Therapeutics, Inc.
CIK 0001479290
Entity typeother
Related Parties
1- filerCIK 0001803375
Filing Metadata
- Form type
- 4
- Filed
- Aug 14, 8:00 PM ET
- Accepted
- Aug 15, 4:15 PM ET
- Size
- 6.9 KB